--- title: "Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor" type: "News" locale: "en" url: "https://longbridge.com/en/news/269356332.md" description: "Formation Bio has acquired global rights, excluding Greater China, to Lynk Pharma's TYK2 inhibitor, LNK01006. This CNS-penetrant drug will be developed by Formation's subsidiary, Bleecker Bio. Lynk will receive a minority stake in Bleecker, upfront and milestone payments up to $605m, and tiered royalties. The drug has FDA IND clearance for trials in the US. Formation plans a Phase I trial in 2026, aiming to expand its clinical-stage portfolio. Lynk focuses on immunology and inflammatory diseases." datetime: "2025-12-11T09:15:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/269356332.md) - [en](https://longbridge.com/en/news/269356332.md) - [zh-HK](https://longbridge.com/zh-HK/news/269356332.md) --- # Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor LNK01006 is a next-generation CNS-penetrant. Credit: MY STOCKERS/Shutterstock.com. Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals. This next-generation central nervous system (CNS)-penetrant will be developed by Bleecker Bio, a newly established subsidiary of Formation. ### Go deeper with GlobalData - ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png) Reports #### NPVM: Aptose Biosciences Inc's Tuspetinib - ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png) Reports #### NPVM: Kymera Therapeutics Inc's KT-413 ##### Go deeper with GlobalData The gold standard of business intelligence. Find out more #### Discover B2B Marketing That Performs Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms. Find out more Lynk Pharmaceuticals will obtain a minority equity stake in Bleecker, along with an upfront payment and potential milestone payments that could reach $605m. The deal also includes tiered royalties on any future sales of the asset. US-based investment fund Pacific Bridge is participating as a minority joint investor in Bleecker. The asset recently received US Food and Drug Administration (FDA) investigational new drug (IND) clearance, allowing the commencement of first-in-human trials in the US. GlobalData Strategic Intelligence # US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Formation intends to begin a Phase I trial in the first half of 2026, as part of its strategy to expand its portfolio of clinical-stage assets. LNK01006 offers selective inhibition of TYK2-mediated cytokine signalling and features a pharmacological profile tailored for central immune system modulation. The pharmacologic profile of the therapy may allow for the exploration of indications where central or compartmentalised immune pathways are considered important. Formation Bio chief business officer David Steinberg stated: “This asset represents a prime example of what we call our ‘Known In New’ strategy of applying validated mechanisms to novel areas of high unmet need. “Leveraging world class human expertise, robust clinical data sets and homegrown, state-of the-art AI tools, we’ve developed deeply grounded hypotheses around novel therapeutic applications of clinically de-risked asset classes.” Lynk Pharmaceuticals is a clinical-stage company focused on discovering and developing medicines for immunology and inflammatory diseases. Lynk Pharmaceuticals CEO Zhao-Kui (ZK) Wan stated: “We are excited to partner with Formation Bio to advance LNK01006 into the clinic. “Formation’s experienced clinical development team and AI-enabled capabilities provide the ideal environment to translate this compound’s scientific potential into meaningful patient impact.” ## Pharmaceutical Technology Excellence Awards - Nominations Closed Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact. **Excellence in Action** Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development. Discover the Impact ## Related News & Research - [Genexine’s First-in-Class SOX2 Degrader GX-BP1 Demonstrates Up to 96% TGI and Eliminates Tumor Regrowth in Preclinical Models](https://longbridge.com/en/news/284421863.md) - [Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 | ACRS Stock News](https://longbridge.com/en/news/284268134.md) - [GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute](https://longbridge.com/en/news/284312081.md) - [Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies | ONNVF Stock News](https://longbridge.com/en/news/283899358.md) - [](https://longbridge.com/en/news/284229871.md)